A Novel Medication to Help Quit Smoking
In May 2006, the U.S. Food and Drug Administration (FDA) approved the medication Chantix (varenicline tartrate) to help cigarette smokers stop smoking . Chantix received a priority FDA review because of its potential, important benefit to public health.
Varenicline tartrate is unique in that it mimics the actions of nicotine on the brain and can help both in easing nicotine withdrawal symptoms and blocking the reinforcing effects of nicotine if smoking is resumed. Two reports in the August 14/28, 2006 issue of the Archives of Internal Medicine have demonstrated the effectiveness of varenicline in both short- and long-term smokers who wish to quit smoking. The researchers report that treatment with varenicline tartrate led to response rates three times higher than placebo in smokers aged 18 to 65 who were attempting to quit smoking.
Previously available smoking cessation treatments include nicotine replacement therapy (gum, nasal spray, patches, and inhalers) and the antidepressants bupropion hydrochloride (Zyban), and nortriptyline hydrochloride. All of these treatments have limited efficacy, with success rates ranging from 7 to 30% in clinical studies. Future studies must be carried out to determine the effectiveness of varenicline (Chantix) treatment compared with each of these established smoking cessation therapies.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions